Published online before print October 21, 2002, doi: 10.1161/01.CIR.0000036082.04708.83
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:2588.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
Hypotension Caused by Extracorporeal Circulation
Serotonin From Pump-Activated Platelets Triggers Nitric Oxide Release
From the Laboratory for Physiology, Institute for Cardiovascular Research, Vrije Universiteit Medical Center, Amsterdam (P.B., G.J.T.), and the Department of Psychiatry, Erasmus University, Rotterdam (D.F.), The Netherlands.
Reprint requests to P. Borgdorff, PhD, Laboratory for Physiology, VUMC, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands. E-mail p.borgdorff.physiol{at}med.vu.nl
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Cardiopulmonary bypass and hemodialysis often cause hypotension. We investigated a possible role of pump-induced platelet activation with consequent serotonin release.
Methods and Results— In rats, a heparin-coated extracorporeal shunt was placed between the proximal part of a carotid artery and the distal part of a femoral artery. Autoperfusion did not affect platelets or hemodynamics. Pump perfusion, however, immediately elicited strong platelet aggregation, whereas aortic pressure rapidly fell to 60±12% (mean±SD) of its prepump value, partially recovered, and then progressively decreased to 70±12% at 2 hours. Femoral resistance doubled and then decreased to 59±11%. The initial changes in aortic pressure and femoral resistance were proportional to the amount of platelet aggregation, were accompanied by a rise (6-fold) in plasma serotonin levels downstream of the pump, but not in the aorta, and could be mimicked by serotonin-infusion into the leg. All hemodynamic changes were prevented or largely reduced by blockade of 5-hydroxytryptamine (5-HT)2 receptors with pizotifen or ritanserin. The hypotension and femoral resistance decrease could also be prevented or abolished by inhibiting the production of nitric oxide (NO), an intermediate in 5-HT2B receptor-induced vasodilation. When the extracorporeal blood was pumped into the aortic arch instead of the femoral artery, the hypotensive effect was similar and also NO dependent, but it was absent with venous return.
Conclusions— Pump perfusion with arterial return of the blood causes hypotension by endothelial NO-release, which in turn is triggered by serotonin from activated platelets.
Key Words: platelets • endothelium • receptors • vasodilation • stress
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Use of extracorporeal systems in cardiopulmonary bypass and hemodialysis often causes severe hypotension. The etiology of this important predictor for mortality and morbidity is still unknown.1,2 One cause might be platelet aggregation with subsequent release of serotonin (5-hydroxytryptamine [5-HT]) and adenosine diphosphate (ADP). Although serotonin is often thought to induce vasoconstriction only,3 its vasodilating properties are important as well. The latter can be mediated by various receptors, of which the 5-HT2B receptors are the most sensitive and widespread. They stimulate endothelium-dependent release of nitric oxide (NO).4–6 In fact, several authors have reported platelet activation7,8 or increased levels of serotonin3,7 or NO9,10 during both intradialytic hypotension and cardiopulmonary bypass.
Platelets are activated even in heparin-coated systems,11,12 although such systems are known to reduce complement and contact activation,13,14 as well as platelet adhesion.15 Hence, factors other than blood-material contact must be involved. By monitoring platelet aggregation continuously, we were recently able to demonstrate that platelets in human and rat blood are activated by use of a roller pump.16 Furthermore, when a simple coated tube was placed between the proximal part of a carotid artery and the distal part of a femoral artery in rats, pump-induced platelet aggregation was accompanied by systemic hypotension, and both could be prevented with aurintricarboxylic acid. This is a specific inhibitor of shear-stress–induced platelet activation that blocks the binding of von Willebrand factor to platelet glycoprotein Ib.17 In the present study, we measured the level of serotonin during pump-induced platelet aggregation within a heparin-coated shunt, tested whether the hypotension could be prevented by blockade of 5-HT2B receptors or inhibition of NO-synthase, and tested whether it could occur with venous or aortic return of the pumped blood.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals and Extracorporeal Circuit
Male Wistar rats (315 to 430 g; Harlan, Zeist, The Netherlands) were anesthetized with ketamine (Kombivet; 60 mg/kg IM) and pentobarbital (Nembutal; 35 mg/kg IP, followed by 10 to 14 mg/kg per hour IV). The animals were ventilated with an air/oxygen mixture (3:1) at 90 breaths/min. Tidal volume was adjusted to provide an arterial pCO2 of
40 mm Hg; arterial pH was between 7.35 to 7.39 and pO2 between 81 to 133 mm Hg. Body temperature was servo-controlled at 37.5°C. Handling of the animals was in compliance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85-23, revised 1985).
After heparinization (Leo Pharma; 800 IU/kg), the proximal part of a carotid artery was cannulated and interconnected with medical grade polyvinyl chloride tubing (circa [ca] 45 cm long, 1.5 mm internal diameter [ID]) to the distal part of a femoral artery, creating blood flow by autoperfusion. Part of this shunt consisted of a peristaltic polyvinyl chloride tube (1.65 mm ID, Gilson), loosely positioned in a small noncommercial roller pump that was still switched off. The rotator of the pump had a diameter of 31 mm and contained 8 rollers with a diameter of 6 mm. All tubing was coated with Duraflow-II heparin by Edwards Lifesciences and was primed with gelofusine, a colloid osmotic solution (Braun). During the connection procedure, flow to the leg was interrupted for 2 to 3 minutes only. For transition from autoperfusion to pump flow, the peristaltic tube was compressed by tightening the rollers of the pump with a calibrated screw until flow stopped; the pump was then started and the speed (ca 20 rpm) was adjusted to make flow equal to autoperfusion (ca 2 mL/min), as measured with an inline flow probe (1N, Transonic). Aortic and femoral pressure were measured with Statham P23 Db pressure transducers via stainless steel T-pieces in the shunt 3 cm from the cannulas. Femoral resistance was continuously derived from the ratio of mean femoral artery pressure and flow, enabling the use of the leg for bioassay. Heart rate was derived from the aortic pressure pulse. Blood was shunted from a carotid artery into the inferior caval vein via a femoral vein in a second set of experiments, and from a femoral artery into the aortic arch via a carotid artery in a third set.
Measurement of Platelet Behavior and Serotonin Levels
Platelet aggregation was continuously measured with a photometric device in the tube downstream from the pump, employing the increase in light transmission through flowing blood during passage of platelet aggregates.18 For quantification, the signals were converted to uniform spikes and counted over periods of 10 seconds. Platelet number and volume in systemic blood were determined using a Helios cell counter (ABX Diagnostics), with values being corrected for changes in hematocrit (see below).
For measurement of plasma serotonin, 0.4 mL blood was collected via both T-pieces, mixed with 0.1 mL K3-EDTA (final concentration: 5 mmol/L), and centrifuged at 3300g for 20 minutes at room temperature. The platelet poor plasma was decanted and frozen at -70°C until analysis. The concentrations of serotonin and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) were measured twice by high performance liquid chromatography (electrochemical detection with limit in plasma: 1 nmol/L). The mean recovery (± SD) of 5-HT added to plasma was 95±7% and of 5-HIAA was 72±8%.19 The results were corrected for dilution using the change in hematocrit because each blood sample from the animal was replaced by an equivalent amount of gelofusine to avoid destabilization of blood pressure.
Serotonin-2–Receptor Blockade and NO-Synthase Inhibition
We used either pizotifen maleate (SanverTech; 3 mg/kg IP) or ritanserin (50 µg/kg IV) to block 5-HT2B receptors. Dose-efficacy of the 5-HT2 blockers was tested in separate animals with 2 doses of serotonin (MSD), infused before the femoral cannula. NO-synthase was inhibited with N
-nitro-L-arginine (L-NA, 6 mg/kg IV). Ritanserin, L-NA, and arginine vasopressin were obtained from Sigma-Aldrich. Ritanserin was dissolved in methanol (750 µg/mL) and subsequently diluted with saline to 75 µg/mL. This vehicle had no effect on the hemodynamic variables or pump-induced responses. All other agents were dissolved in saline.
Statistics
Values in the text and legends are expressed as mean±SD; the percentage values in figures and the table are expressed as mean±SEM. Simple time series data were analyzed by 1-way ANOVA, whereas time series data with different conditions were analyzed with 2-way ANOVA, both for repeated measurements. For subsequent comparison of individual time-points, Bonferroni’s multiple comparison test was used. Differences were considered statistically significant if P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Hypotensive Effect of Pump Perfusion and Role of Platelet Aggregation
During autoperfusion into the femoral bed, no platelet aggregation was observed, and aortic pressure, heart rate, and femoral vascular resistance remained stable. On commencement of pump perfusion, however, platelets started to aggregate (Figure 1). Aggregation was maximal within the first 3 to 5 minutes, then leveled off but remained present for the next 2 hours of pumping. During the strong platelet aggregation, aortic pressure fell to about 60% of its initial value, and then partially recovered. Heart rate decreased temporarily to about 90% of initial (373±23 b/min, P<0.03). Femoral resistance showed a triphasic reaction; after a short decrease (<1 minute) and a 2-fold increase (about 5 minutes), it ended in a long-lasting decrease to about 60%. The rise in femoral resistance started 10 to 20 seconds before the fall in aortic pressure. Figure 2 presents mean changes during 2 hours of pump perfusion (solid squares, n=6), showing that after half an hour, aortic pressure started to fall again, slowly approximating 70% of its prepump value; during this period, heart rate did not change. When, after 2 hours, the pump was switched off, aortic pressure and femoral resistance did not recover.
|
|
During pump perfusion, platelet number and volume decreased by 18% (from 833±62 to 680±77 109/L) and 4% (from 5.2±0.3 to 5.0±0.2 fL), respectively (P<0.0001, n= 19). These changes did not occur during 2 hours of autoperfusion, ie, when the pump was off (n=6).
Figure 3 shows that both the initial pressure decrease and femoral resistance increase were linearly related to the amount of platelet aggregation, suggesting a causal relation.
|
Serotonin and 5-HT2 Receptor Blockade
Figure 4A shows that shortly after pump start, the plasma serotonin level was strongly elevated in the femoral artery (from 12±6.5 nmol/L to 54±21 nmol/L in the first and 75±56 nmol/L in the third minute), but not in carotid blood (hatched bars). The elevation was positively related to the amount of platelet aggregation during the first 5 minutes (correlation coefficient [R]: 0.69, P<0.04, n=9). In the seventh and seventeenth minutes, when platelet aggregation had declined, serotonin levels in blood flowing into the hind leg had also declined (to 146±36% and 140±38% of prepump value, respectively; P<0.07), whereas systemic levels of its metabolite showed a significant incremental trend (Figure 4B).
|
Interestingly, the hemodynamic changes during pumping could be mimicked by serotonin infusion into the leg (Table). A dose of 4 to 6 µg · kg-1 · min-1 (right column) elicited a similar decrease in aortic pressure and rise in femoral resistance as observed shortly after onset of pump perfusion, and heart rate also slowed down to 90±2% of initial. A 5 to 10x lower dose (0.5 to 1 µg · kg-1 · min-1; left column), did not influence aortic pressure or heart rate but diminished femoral resistance to a similar extent as seen after some minutes of pump perfusion.
|
Blockade of 5-HT2B receptors with pizotifen (Figure 2, open triangles, n=8) or ritanserin (open circles, n=5) inhibited or largely reduced the initial and later part of the pump-induced fall in blood pressure and the temporal decrease in heart rate, just as they blocked the effect of serotonin infusion into the leg (4 to 6 µg · kg-1 · min-1; Table). Because pizotifen lowered basal aortic pressure (to about 71% of initial), 3 additional experiments were performed, restoring pressure before pump start with vasopressin (ca 5 µg · kg-1 · h-1 IV). Also in these experiments, pizotifen prevented the pump-induced hypotension (pressure at 120 minutes: 104±5% of initial). Both antagonists also prevented the rise in femoral resistance and even turned it into vasodilation, but only partially reduced the long-lasting fall in femoral resistance (Figure 2B).
The 5-HT2 receptor antagonists did not significantly diminish pump-induced platelet aggregation during the first 5 minutes (control: 1064±491, pizotifen: 1096±614, and ritanserin: 848±425 aggregates per mL blood). This indicates that their inhibition of the initial pressure and resistance changes (Figure 2) could not be ascribed to diminution of platelet aggregation, but were mediated by vascular receptor blockade.
Nitric Oxide Synthase Inhibition
Because vasodilation by 5-HT2 receptor stimulation is known to be mediated by NO, we also inhibited NO-synthase (NOS). Figure 5 shows that NOS-inhibition completely prevented the decrease of aortic pressure and femoral resistance during pumping (P<0.0001, n=6), but did not abolish the initial vasoconstriction. The amount of platelet aggregates during the first 5 minutes (1069±510 aggregates per mL blood) did not significantly differ from control (1064±491). When L-NA was administered not before but at 2 hours after pump start (see arrow in Figure 5), pressure and resistance recovered and even showed an overshoot (from 70±11.7% to 117±10.7% and from 59±11.0% to 137±19.2%, respectively; n=6).
|
Arterial Versus Venous Return
Although the prevention of hypotension by 5-HT2B receptor blockade indicates a role for serotonin, no significant increase in serotonin was observed in carotid artery blood during the first minutes after pump start (Figure 4). This suggests that factors other than serotonin are involved as well, eg, longer acting vasodilators released by local serotonergic stimulation of endothelium in the hind leg. When we bypassed the femoral bed by returning the extracorporeal blood directly into the inferior caval vein, the fall in blood pressure after pump start was indeed much smaller (see Figure 6, open circles; n=6), whereas its later course was not different from that found with autoperfusion (filled triangles, n=6). When, instead, the blood was returned into the aortic arch (open triangles, n=6), blood pressure decreased in a way similar to when given into the femoral artery (solid squares, n=6), though it was somewhat less pronounced during the first 10 minutes. In all these conditions, the blood pressure decrease at 2 hours could be made undone with NO-synthase inhibition.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Use of extracorporeal blood circuits in patients often causes hypotension, even when the system is coated with heparin. Simulating this serious clinical problem in a rat-model, we found that the platelet activation caused by a roller pump leads to serotonin release and, in case of arterial return of the blood, to a subsequent increase in nitric oxide production.
Role of Serotonin and Nitric Oxide in Pump-Induced Hypotension
Several of our results indicate that platelet serotonin release and increase of endothelial NO-production importantly contributed to the pump-induced hypotension. First, the degrees of initial hypotension and increase in plasma serotonin (4- to 6-fold) during the first minutes were both linearly related to the amount of platelet aggregation. Second, serotonin infusion into the femoral artery could mimic the decrease in aortic pressure. Third, the hypotension could be prevented by 5-HT2 receptor blockade or inhibition of NO production, the intermediate in 5-HT2B receptor-induced vasodilation.5,6. Our data also indicate that during pumping NO-release was continuously elevated; when NO-synthase was inhibited after 2 hours of pumping, both aortic pressure and femoral resistance approximately doubled. These effects are too large to be solely caused by inhibition of normal NO production, which yielded increases of about 25% only.
Pumping elicited hypotension when the blood was returned arterially, either into the femoral bed or via the aortic arch, but had only little effect with blood returned into the caval vein (Figure 6). In the latter condition, an important part of the platelet-released serotonin was apparently cleared by the lungs.20 With aortic return, the increased level of serotonin will have influenced resistance vessels in multiple organs. In case of femoral return, however, it is not immediately clear how serotonin caused systemic hypotension because it had to pass the lungs and its level had decreased to almost normal in carotid artery blood (Figure 4). Probably, the strong local serotonergic activation of endothelial cells in the leg elicited, via elevated nitric oxide production, release of longer-acting circulating factors, like NO-derived compounds21 and/or prostacyclin.22,23 Pilot experiments with femoral return indeed showed that the initial hypotension did not occur when 5-HT2 receptors in the femoral bed were locally blocked. Blockade was realized by infusing, during 5 minutes around pump start, with a low dose of ritanserin (5 µg/kg, n=2) or pizotifen (40 µg/kg, n=2) into the femoral return line. The efficacy of these doses was proven by the absence of changes in femoral resistance during an infusion of serotonin that still elicited systemic hypotension.
The 2 serotonin-2–receptor antagonists used in this study not only prevented the pump-induced hypotension, which is likely explained by their blockade of 5-HT2B receptors, but also the temporal rise in femoral resistance. This is probably the result of the close homology of the subclasses of 5-HT2 receptors, which causes antagonists like ritanserin and pizotifen to suppress the action of both the vasoconstricting 5-HT2A receptors and the vasodilating 5-HT2B receptors.4,24–26 Because the latter are known to be more sensitive to serotonin than 5-HT2A receptors, the triphasic reaction of femoral resistance after pump start (fall–rise–fall) corresponds well to an increasing and decreasing serotonin concentration in the leg. The third phase of the reaction, ie, the long-lasting vasodilation, however, was only partially inhibited by 5-HT2–receptor blockade (Figure 2). This suggests that in the femoral bed, where serotonin concentrations would have been higher than in the systemic circulation, vasodilating serotonin receptors other than 5-HT2B were stimulated as well. Candidates are 5-HT1A receptors on the endothelium,27 5-HT1B on sympathetic nerve endings,24 and 5-HT7 on vascular smooth muscle cells.5,28 When, however, in combination with 5-HT2 receptor blockade, all these receptors were inactivated simultaneously with, respectively, BMY 7378,27 denervation of the leg, and lisuride, 28 pump perfusion still elicited some vasodilation, although serotonin-infusion did not (data not shown). Therefore, platelet release products other than serotonin, like ADP, were probably involved as well.
Platelet aggregation was strong during the first minutes after pump start, but then diminished. This diminishment was not caused by platelet consumption alone, as the loss of platelets after 2 hours of pumping was 18% only. The release of serotonin and the small, though highly significant decrease of mean platelet volume (from 5.2 to 5.0 fL), suggest that the ability of platelets to aggregate soon diminished as a result of degranulation. Similarly, human platelets become less dense during cardiopulmonary bypass, apparently by release of serotonin and other granular contents;29 they seem to maintain their integrity, but lose functionality.8
Clinical Interest
We showed that heparin coating of an extracorporeal device does not prevent the shear stress-dependent platelet aggregation and platelet loss induced by a roller pump. This may explain why bleeding problems in the clinical setting are not prevented by coating the system with heparin.11 The subsequent release of serotonin and the 5-HT2B receptor-mediated NO-production might cause hypotension. This is especially true for cardiopulmonary bypass, where blood is returned into the aorta and clearance of serotonin is compromised by stagnation of pulmonary flow. However, patients on hemodialysis also seem at risk; although in our experiments on rats, hypotension remained absent when the blood was returned intravenously, as in hemodialysis, the clearance of serotonin by the lungs might be impaired in uremic patients because their basic level of serotonin is known to be elevated.30 It has indeed been reported that in cardiopulmonary bypass and hemodialysis, platelets are activated,7,8 and the levels of both serotonin3,7 and NO synthesis are increased.9,10,31 The prevention of pump-induced hypotension by 5-HT2B–receptor blockade in this study suggests that 5-HT2–receptor antagonists may be candidates for clinical use. The same might hold for inhibitors of NO-synthase, as suggested also by Peer et al,32 or substances able to prevent shear-induced platelet aggregation.
In conclusion, our animal studies with a heparinized extracorporeal shunt indicate that, at least in situations of arterial blood return, the hypotensive effect of pump perfusion is caused by endothelial release of NO, which in turn is triggered by serotonin from aggregating platelets.
|
Acknowledgments |
|---|
We thank Edwards Lifesciences for coating our tubing with Duraflow II heparin, and Astrid van Dalen for expert technical assistance.
Received May 8, 2002; revision received August 12, 2002; accepted August 16, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Reich DL, Bodian CA, Krol M, et al. Intraoperative hemodynamic predictors of mortality, stroke, and myocardial infarction after coronary artery bypass surgery. Anesth Analg. 1999; 89: 814–822.
2. Zucchelli P, Santoro A. Dialysis-induced hypotension: a fresh look at pathophysiology. Blood Purif. 1993; 11: 85–98.[CrossRef][Medline] [Order article via Infotrieve]
3. Reneman RS, Van der Starre PJ. Serotonin and acute cardiovascular disorders. Cardiovasc Drugs Ther. 1990; 4 (suppl 1): 19–25.
4. Watts SW, Cohen ML. Vascular 5-HT receptors: pharmacology and pathophysiology of 5-HT1B, 5-HT1D, 5-HT1F, 5-HT2B and 5-HT7 receptors. Neurotransmissions, Sigma-RBI. 1999; 15: 3–15.
5. Ullmer C, Schmuck K, Kalkman HO, et al. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett. 1995; 370: 215–221.[CrossRef][Medline] [Order article via Infotrieve]
6. Ellis ES, Byrne C, Murphy OE, et al. Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol. 1995; 114: 400–404.[Medline] [Order article via Infotrieve]
7. De Sanctis LB, Stefoni S, Cianciolo G, et al. Effect of different dialysis membranes on platelet function: a tool for biocompatibility evaluation. Int J Artif Organs. 1996; 19: 404–410.[Medline] [Order article via Infotrieve]
8. Friedenberg WR, Myers WO, Plotka ED, et al. Platelet dysfunction associated with cardiopulmonary bypass. Ann Thorac Surg. 1978; 25: 298–305.[Abstract]
9. Yokokawa K, Mankus R, Saklayen MG, et al. Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med. 1995; 123: 35–37.
10. Ruvolo G, Speziale G, Greco E, et al. Nitric oxide release during hypothermic versus normothermic cardiopulmonary bypass. Eur J Cardiothorac Surg. 1995; 9: 651–654.[Abstract]
11. Boonstra PW, Gu YJ, Akkerman C, et al. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994; 107: 289–292.
12. Muehrcke DD, McCarthy PM, Kottke-Marchant K, et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial. J Thorac Cardiovasc Surg. 1996; 112: 472–483.
13. te Velthuis H, Baufreton C, Jansen PG, et al. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J Thorac Cardiovasc Surg. 1997; 114: 117–122.
14. Jansen PG, te Velthuis H, Huybregts RA, et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg. 1995; 110: 829–834.
15. Takano H, Nakano S, Kadoba K, et al. Evaluation of the biocompatibility of a new method for heparin coating of a cardiopulmonary bypass circuit. ASAIO J. 1992; 38: M390–M394.[Medline] [Order article via Infotrieve]
16. Borgdorff P, van Den Berg RH, Vis MA, et al. Pump-induced platelet aggregation in albumin-coated extracorporeal systems. J Thorac Cardiovasc Surg. 1999; 118: 946–952.
17. Borgdorff P, van den Bos G, Tangelder GJ. Extracorporeal circulation can induce hypotension by both blood-material contact and pump-induced platelet aggregation. J Thorac Cardiovasc Surg. 2000; 120: 12–19.
18. Borgdorff P, Kok WE, Vis MA, et al. Vasodilation by shear-induced platelet aggregation in extracorporeal circuits. Am J Physiol. 1994; 266(3 Pt 2): H891–H897.
19. Fekkes D, Timmerman L, Pepplinkhuizen L. Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression. Eur Neuropsychopharmacol. 1997; 7: 235–239.[CrossRef][Medline] [Order article via Infotrieve]
20. Pitt BR, Hammond GL, Gillis CN. Comparison of pulmonary and extrapulmonary extraction of biogenic amines. J Appl Physiol. 1982; 52: 1545–1551.
21. Stamler JS, Simon DI, Osborne JA, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A. 1992; 89: 444–448.
22. Luscher TF. Platelet-vessel wall interaction: role of nitric oxide, prostaglandins and endothelins. Baillieres Clin Haematol. 1993; 6: 609–627.[CrossRef][Medline] [Order article via Infotrieve]
23. Wang W, Diamond SL. Does elevated nitric oxide production enhance the release of prostacyclin from shear stressed aortic endothelial cells? Biochem Biophys Res Commun. 1997; 233: 748–751.[CrossRef][Medline] [Order article via Infotrieve]
24. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994; 46: 157–203.[Abstract]
25. Bonhaus DW, Bach C, DeSouza A, et al. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol. 1995; 115: 622–628.[Medline] [Order article via Infotrieve]
26. Glusa E, Pertz HH. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 2000; 130: 692–698.[CrossRef][Medline] [Order article via Infotrieve]
27. Verbeuren TJ, Mennecier P, Laubie M. 5-Hydroxytryptamine-induced vasodilatation in the isolated perfused rat kidney: are endothelial 5-HT1A receptors involved? Eur-J-Pharmacol. 1991; 201: 17–27.[CrossRef][Medline] [Order article via Infotrieve]
28. De Vries P, De Visser PA, Heiligers JP, et al. Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats. Naunyn Schmiedebergs Arch Pharmacol. 1999; 359: 331–338.[CrossRef][Medline] [Order article via Infotrieve]
29. van Oost B, Hien-Hagg IH, Timmermans AP, et al. The effect of thrombin on the density distribution of blood platelets: detection of activated platelets in the circulation. Blood. 1983; 62: 433–438.
30. Pawlak D, Malyszko J, Malyszko JS, et al. Peripheral serotonergic system in uremia. Thromb Res. 1996; 83: 189–194.[CrossRef][Medline] [Order article via Infotrieve]
31. Nishimura M, Takahashi H, Yoshimura M. Role of nitric oxide in haemodialysis hypotension. Acta Physiol Scand. 2000; 168: 181–186.[CrossRef][Medline] [Order article via Infotrieve]
32. Peer G, Itzhakov E, Wollman Y, et al. Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension. Nephrol Dial Transplant. 2001; 16: 1436–1441.
This article has been cited by other articles:
 |
|
 |
|
  M. Gritters, P. Borgdorff, M. P. C. Grooteman, M. Schoorl, M. Schoorl, P. C. M. Bartels, G.-J. Tangelder, and M. J. Nube Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility? Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2911 - 2917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. M. Fischer, R. Schindler, K. Brixius, U. Mehlhorn, and W. Bloch Extracorporeal Circulation Activates Endothelial Nitric Oxide Synthase in Erythrocytes Ann. Thorac. Surg., December 1, 2007; 84(6): 2000 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Borgdorff, G. J. Tangelder, and W. J. Paulus Cyclooxygenase-2 Inhibitors Enhance Shear Stress-Induced Platelet Aggregation J. Am. Coll. Cardiol., August 15, 2006; 48(4): 817 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Borgdorff and G. J. Tangelder Pump-induced platelet aggregation with subsequent hypotension: Its mechanism and prevention with clopidogrel J. Thorac. Cardiovasc. Surg., April 1, 2006; 131(4): 813 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. C. Grooteman and M. J. Nube Impact of the type of dialyser on the clinical outcome in chronic haemodialysis patients: does it really matter? Nephrol. Dial. Transplant., December 1, 2004; 19(12): 2965 - 2970. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Randriamboavonjy, J. Schrader, R. Busse, and I. Fleming Insulin Induces the Release of Vasodilator Compounds From Platelets by a Nitric Oxide-G Kinase-VAMP-3-dependent Pathway J. Exp. Med., February 2, 2004; 199(3): 347 - 356. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||